Repaglinide versus glyburide: A one-year comparison trial

Diabetes Research and Clinical Practice

Volumn 43, Issue 3, 1999, Pages 155-166

  Marbury, Thomas ^a   Huang, Won Chin ^b   Strange, Poul ^b   Lebovitz, Harold ^c  

^a ORLANDO CLINICAL RESEARCH CENTER   (United States)

^b NOVO NORDISK INC   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Glyburide; Oral hypoglycemic agents; Phase III study; Repaglinide; Type 2 diabetes

Indexed keywords

C PEPTIDE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; REPAGLINIDE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE HOMEOSTASIS; HEADACHE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREMOR; VERTIGO;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; CARBAMATES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PIPERIDINES; PROSPECTIVE STUDIES; TRIGLYCERIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0032905967     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(99)00002-9     Document Type: Article

References (24)

1. Baliga B.S., Fonseca V.A. Recent advances in the treatment of type 2 diabetes mellitus. Am. Fam. Phys. 55:1997;817-824.
2. Harris M.I. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 16:1993;642-652.
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20 (1997) 1183-1197.
4. Delprato S., Matsuda M., Simonson D.C., Groop L.C., Sheehan P. et al. Studies on the mass-action effect of glucose in NIDDM and IDDM-evidence for glucose resistance. Diabetologia. 40:1997;687-697.
5. Klein R., Klein B.E., Moss S.E. Relation of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann. Intern. Med. 124:1996;90-96.
6. Koopmans S.J., Ohman L., Haywood J.R., Mandarino L.J., DeFronzo R.A. Seven days of euglycemic hyperinsulinemia induces insulin-resistance for glucose metabolism, but not hypertension, elevated catecholamine levels or increased sodium retention in conscious normal rats. Diabetes. 46:1997;1572-1578.
7. Lehto S., Ronnemaa T., Haffner S.M., Pyorala K., Kallio V., Laakso M. Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes. 46:1997;1354-1359.
8. Henquin J.-C., Garrino M.-G., Nenquin M. Stimulation of insulin release by benzoic acid derivatives related to the non-sulfonylurea moiety of glibenclamide: structural requirements and cellular mechanisms. Eur. J. Pharmacol. 141:1987;243-251.
9. J. Fuhlendorff, H. Kofod, Repaglinide and glibenclamide regulate the ATP sensitive potassium channel through different binding sites, Eur. J. Endocrinol. 132 (Suppl. 1) (1995) (Abstract 5).
10. Fuhlendorff J., Rorsman P., Kofod H. et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes. 47:1998;1-7.
11. Malaisse W.J. Stimulation of insulin release by non-sulfonylurea hypoglycemic agents: The meglitinide family. Horm. Metab. Res. 27:1995;263-266.
12. Melander A. Oral antidiabetic drugs: an overview. Diabetic Med. 13:1996;S143-S147.
13. Graul A., Castner J. Repaglinide. Drugs Future. 21:1996;694-699.
14. Goldberg R.B., Einhorn D., Lucas C.P. et al. A randomized, placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes. 47:1998;98. Abstract 383.
15. B. Tronier, T.C. Marbury, P. Damsbo, K.A. Windfeld, A new oral hypoglycaemic agent, repaglinide minimizes risk of hypoglycaemia in well controlled type 2 diabetic patients, presented at the 55th Annual Meeting of the American Diabetes Association, Atlanta, GA, June 10-13 1995 (Abstract 261).
16. Profozic V., Babic D., Renar I. et al. Benzoic acid derivative hypoglycemic activity and pharmacokinetics in non-insulin dependent diabetic patients. Diabetol. Croat. 25:1996;109-116.
17. L.F. Van Gaal, K.L. Van Acker, P. Damsbo, I.H. De Leeuw, Metabolic effects of repaglinide, a new oral hypoglycaemic agent in therapy-naive type 2 diabetics, presented at the 31st Annual Meeting of the European Association for the Study of Diabetes, Stockholm, Sweden, September 12-16 1995 (Abstract 164).
18. Groop L.C. Sulfonylureas in NIDDM. Diabetes Care. 15:1992;737-754.
19. The UK Prospective Diabetes Study Group, Perspectives in diabetes, UK prospective study 16, overview of 6 years therapy of type II diabetes: A progressive disease, Diabetes 44 (1995) 1249-1258.
20. Wolffenbuttel B.H.R., Nijst L., Sels J.P.J.E., Menheere P.P.C.A., Müller P.G., Nieuwenhuijzen-Kruseman A.C. Effects of a new oral hypoglycemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur. J. Clin. Pharmacol. 45:1993;113-116.
21. Vinambres C., Villnueva-Penacarrillo M.L., Valverde I., Mailaisse W.J. Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets. Pharmacol. Res. 34:1996;83-85.
22. Krentz A.J., Ferner R.E., Bailey C.J. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf. 11:1994;223-241.
23. Ovalle F., Fanelli C.G., Paramore D.S., Hershey T., Craft S., Cryer P.E. Brief twice-weekly episodes of hypoglycemia reduce detection of clinical hypoglycemia in type 1 diabetes mellitus. Diabetes. 47:1998;1472-1479.
24. Haffner M., Lehto S., Ronnemaa T., Pyorala K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl. J. Med. 339:1998;229-234.